Your search matched 30 results
The Week That Was: Could President Barbie Take on Drug Pricing? | Blog
How could the recent impeachment inquiry effect drug pricing legislation on the Hill?
The Week That Was: To Infinity and Beyond | Blog
80% of voters support importing drugs from Canada and politicians on both sides of the aisle agree.
The Week That Was: No shortage of highs | Blog
On Wednesday, the House Energy & Commerce Committee held a hearing on safeguarding pharmaceutical supply chains in a global economy, and the discussion included something for everyone.
The Week That Was: "I don't know" x 600 | Blog
Climate change is named a top 10 health threat and we’ve broken down the conundrum for pharma companies regarding activating on the issue.
The Week That Was: Riding the Blues | Blog
Uber recently released a safety report and announced steps it plans to take to address sexual assault in ride shares and provide support for victims.
The Week That Was: From IPO to Tomato | Blog
A recent survey found 70% of investors decreased interest in buying IPOs compared to last spring.
The Week That Was: Could sunny days sweep the opioids away? | Blog
Missed the most recent analysis conducted by ICER?
The Week That Was: Tik Tok Don’t Stop | Blog
“Timing is everything - particularly when lives are at stake.”
The Week That Was: Profits and Plagues | Blog
This week’s edition of The Week That Was details how the Business Roundtable’s “Statement on the Purpose of a Corporation” shifts businesses’ focus from solely shareholders to all stakeholders.
The Week That Was: Come on, show 'em what you're worth | Blog
Policymakers continue their focus on drug pricing and may also have eyes for changes to the Orphan Drug Act.
The Week That Was: A Whole Lotta Firsts | Blog
Funding for federal gun violence research and an early holiday present for biosimilars manufacturers -- We break down the new federal budget as well as news from the ACA’s legal saga in this week’s edition of The Week That Was.
The Week That Was: High Times at CVS | Blog
It’s seems like it’s being marketed as a treatment for everything from pain to anxiety, but is it legal?
The Week That Was: Full-Speed- Ahead Fall | Blog
Congress is back from summer recess and healthcare is top of mind.
The Week That Was: Flying Cat-a-strophe | Blog
It’s been a little over a year since the first crash of a Boeing 737 Max in Indonesia.
The Week That Was: Got Meth or a Bonus? | Blog
A consortium of 300 powerful organizations have filed resolutions demanding research into the feasibility of tying drug pricing to senior executive incentive pay.
The Week That Was: ... | Blog
Our favorite #healthpolicyvalentines, new FDA guidance regarding complex generics and what you need to know now regarding data security from pharma and patient perspectives.
Crowdfunding... the Best a Man Can Get | Blog
SCOTUS is weighing its options on a number of healthcare cases; using social activism to tip the scales for your brand reputation; and crowdfunding for what?
The Week That Was: Hiccups, ICER and IPI | Blog
How will the Institute for Clinical and Economic Review (ICER) reconcile the tug-of-war between the promise and uncertainty in valuing gene therapies?
The Week That Was: Bearing the Market and Blowing the Whistle | Blog
The FDA is expecting to receive more than 200 investigational new drug applications per year for gene therapies, starting in 2020.
The Week That Was: The word of the year: “They” | Blog
Did you hear that the US House of Representatives passed H.R. 3, the Lower Drug Costs Now Act, a sweeping bill designed to lower drug prices?
The Week That Was: Walking on Mars | Blog
From potential drug pricing policies to investor interest in life science companies, there’s a lot of talk around money and medicines right now.
The Week That Was: 20 Hours of in-flight fun? | Blog
Are U.S. sheriffs PhRMA’s new spokespeople?
The Week That Was: Green, Red, White and Blue | Blog
This week's edition of The Week That Was details how health and medical groups are taking action to address the “greatest public health challenge of the 21st century” and what you need to know from a busy week in healthcare policy.
The Week That Was: Farewell, Yellow Brick Road | Blog
As drug pricing continues to be under the microscope, it’s a tough environment for drug makers.
Already have a RSS feed reader?
